組換え血漿タンパク質の世界市場シェアとランキング、全体売上高と需要予測 2024-2030Recombinant Plasma Proteins - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 先天性あるいは後天性の重篤な出血性疾患や免疫疾患の治療に不可欠な凝固因子、抗凝固剤、免疫グロブリン、アルブミンなど、広範な治療用タンパク質の供給源は、ほぼ50年間、ヒト血漿の分画しかなかった。この20... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー先天性あるいは後天性の重篤な出血性疾患や免疫疾患の治療に不可欠な凝固因子、抗凝固剤、免疫グロブリン、アルブミンなど、広範な治療用タンパク質の供給源は、ほぼ50年間、ヒト血漿の分画しかなかった。この20年間で、哺乳類細胞培養への組換え技術の応用により、生産性、コスト、免疫原性リスクにおいていくつかの制約はあるものの、組換え技術が可能になった。組換え血漿タンパク質の世界市場は、2023年には9,200万米ドルと推定され、2024-2030年の予測期間中のCAGRは2.1%で、2030年には1億640万米ドルに再調整されると予測されている。 当社の調査によると、医療機器の世界市場は2023年に6,030億米ドルと推定され、今後6年間は年平均成長率5%で成長する。世界の医療支出は世界GDPの10%を占め、高齢化による健康ニーズの増加、慢性疾患や感染症の流行、新興市場の拡大により、近年増加の一途をたどっている。医療機器市場は、ヘルスケア産業において重要な役割を果たしている。この市場を牽引しているのは、世界的な高度医療サービスに対する需要の高まり、医療技術の進歩、高齢者人口の増加、医療費の増加、病気の早期診断・治療に対する意識の高まりなど、いくつかの要因である。 レポートの範囲 本レポートは、組換え血漿タンパク質の世界市場を包括的に紹介することを目的としており、総売上高、主要企業の市場シェアおよびランキングに焦点を当て、地域別・国別、タイプ別、用途別の組換え血漿タンパク質の分析も併せて掲載しています。 組換え血漿タンパク質の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量分析および定性分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、組換え血漿タンパク質に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 CSL社 シャイアー(武田薬品工業) オクタファーマ ノボ ノルディスク バイエル バイオベラティブ・セラピューティクス社(サノフィ) アプテボ・セラピューティクス ファーミンググループ ファイザー タイプ別セグメント チャイニーズハムスター卵巣(CHO)細胞株 ベビーハムスター腎臓(BHK)細胞株 ヒト胚性腎臓(HEK)細胞株 その他 用途別セグメント 血友病A 血友病B フォンウィルブランド病 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章:報告書のスコープ、世界の総市場規模を紹介します。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章:組換え血漿蛋白質メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章:各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章:組換え血漿タンパク質の地域レベルでの収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章 組換え血漿タンパク質の国別売上高各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章:産業の上流と下流を含む産業チェーンの分析。 第9章:結論 目次1 Market Overview1.1 Recombinant Plasma Proteins Product Introduction 1.2 Global Recombinant Plasma Proteins Market Size Forecast 1.3 Recombinant Plasma Proteins Market Trends & Drivers 1.3.1 Recombinant Plasma Proteins Industry Trends 1.3.2 Recombinant Plasma Proteins Market Drivers & Opportunity 1.3.3 Recombinant Plasma Proteins Market Challenges 1.3.4 Recombinant Plasma Proteins Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Recombinant Plasma Proteins Players Revenue Ranking (2023) 2.2 Global Recombinant Plasma Proteins Revenue by Company (2019-2024) 2.3 Key Companies Recombinant Plasma Proteins Manufacturing Base Distribution and Headquarters 2.4 Key Companies Recombinant Plasma Proteins Product Offered 2.5 Key Companies Time to Begin Mass Production of Recombinant Plasma Proteins 2.6 Recombinant Plasma Proteins Market Competitive Analysis 2.6.1 Recombinant Plasma Proteins Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Recombinant Plasma Proteins Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Proteins as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Chinese Hamster Ovary (CHO) Cell Line 3.1.2 Baby Hamster Kidney (BHK) Cell Line 3.1.3 Human Embryonic Kidney (HEK) Cell Line 3.1.4 Others 3.2 Global Recombinant Plasma Proteins Sales Value by Type 3.2.1 Global Recombinant Plasma Proteins Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Recombinant Plasma Proteins Sales Value, by Type (2019-2030) 3.2.3 Global Recombinant Plasma Proteins Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hemophilia A 4.1.2 Hemophilia B 4.1.3 Von Willebrand Disease 4.1.4 Others 4.2 Global Recombinant Plasma Proteins Sales Value by Application 4.2.1 Global Recombinant Plasma Proteins Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Recombinant Plasma Proteins Sales Value, by Application (2019-2030) 4.2.3 Global Recombinant Plasma Proteins Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Recombinant Plasma Proteins Sales Value by Region 5.1.1 Global Recombinant Plasma Proteins Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Recombinant Plasma Proteins Sales Value by Region (2019-2024) 5.1.3 Global Recombinant Plasma Proteins Sales Value by Region (2025-2030) 5.1.4 Global Recombinant Plasma Proteins Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Recombinant Plasma Proteins Sales Value, 2019-2030 5.2.2 North America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030 5.3.2 Europe Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Recombinant Plasma Proteins Sales Value, 2019-2030 5.4.2 Asia Pacific Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Recombinant Plasma Proteins Sales Value, 2019-2030 5.5.2 South America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Recombinant Plasma Proteins Sales Value, 2019-2030 5.6.2 Middle East & Africa Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Recombinant Plasma Proteins Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Recombinant Plasma Proteins Sales Value 6.3 United States 6.3.1 United States Recombinant Plasma Proteins Sales Value, 2019-2030 6.3.2 United States Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030 6.4.2 Europe Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Recombinant Plasma Proteins Sales Value, 2019-2030 6.5.2 China Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.5.3 China Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Recombinant Plasma Proteins Sales Value, 2019-2030 6.6.2 Japan Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Recombinant Plasma Proteins Sales Value, 2019-2030 6.7.2 South Korea Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Recombinant Plasma Proteins Sales Value, 2019-2030 6.8.2 Southeast Asia Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Recombinant Plasma Proteins Sales Value, 2019-2030 6.9.2 India Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.9.3 India Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 CSL Limited 7.1.1 CSL Limited Profile 7.1.2 CSL Limited Main Business 7.1.3 CSL Limited Recombinant Plasma Proteins Products, Services and Solutions 7.1.4 CSL Limited Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.1.5 CSL Limited Recent Developments 7.2 Shire (Takeda Pharmaceutical Company Limited) 7.2.1 Shire (Takeda Pharmaceutical Company Limited) Profile 7.2.2 Shire (Takeda Pharmaceutical Company Limited) Main Business 7.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Products, Services and Solutions 7.2.4 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments 7.3 Octapharma 7.3.1 Octapharma Profile 7.3.2 Octapharma Main Business 7.3.3 Octapharma Recombinant Plasma Proteins Products, Services and Solutions 7.3.4 Octapharma Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.3.5 Novo Nordisk Recent Developments 7.4 Novo Nordisk 7.4.1 Novo Nordisk Profile 7.4.2 Novo Nordisk Main Business 7.4.3 Novo Nordisk Recombinant Plasma Proteins Products, Services and Solutions 7.4.4 Novo Nordisk Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.4.5 Novo Nordisk Recent Developments 7.5 Bayer 7.5.1 Bayer Profile 7.5.2 Bayer Main Business 7.5.3 Bayer Recombinant Plasma Proteins Products, Services and Solutions 7.5.4 Bayer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.5.5 Bayer Recent Developments 7.6 Bioverativ Therapeutics, Inc. (Sanofi) 7.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Profile 7.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Main Business 7.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Products, Services and Solutions 7.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Developments 7.7 Aptevo Therapeutics 7.7.1 Aptevo Therapeutics Profile 7.7.2 Aptevo Therapeutics Main Business 7.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Products, Services and Solutions 7.7.4 Aptevo Therapeutics Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.7.5 Aptevo Therapeutics Recent Developments 7.8 Pharming Group 7.8.1 Pharming Group Profile 7.8.2 Pharming Group Main Business 7.8.3 Pharming Group Recombinant Plasma Proteins Products, Services and Solutions 7.8.4 Pharming Group Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.8.5 Pharming Group Recent Developments 7.9 Pfizer 7.9.1 Pfizer Profile 7.9.2 Pfizer Main Business 7.9.3 Pfizer Recombinant Plasma Proteins Products, Services and Solutions 7.9.4 Pfizer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.9.5 Pfizer Recent Developments 8 Industry Chain Analysis 8.1 Recombinant Plasma Proteins Industrial Chain 8.2 Recombinant Plasma Proteins Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Recombinant Plasma Proteins Sales Model 8.5.2 Sales Channel 8.5.3 Recombinant Plasma Proteins Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryFor almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks- Table of Contents1 Market Overview1.1 Recombinant Plasma Proteins Product Introduction 1.2 Global Recombinant Plasma Proteins Market Size Forecast 1.3 Recombinant Plasma Proteins Market Trends & Drivers 1.3.1 Recombinant Plasma Proteins Industry Trends 1.3.2 Recombinant Plasma Proteins Market Drivers & Opportunity 1.3.3 Recombinant Plasma Proteins Market Challenges 1.3.4 Recombinant Plasma Proteins Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Recombinant Plasma Proteins Players Revenue Ranking (2023) 2.2 Global Recombinant Plasma Proteins Revenue by Company (2019-2024) 2.3 Key Companies Recombinant Plasma Proteins Manufacturing Base Distribution and Headquarters 2.4 Key Companies Recombinant Plasma Proteins Product Offered 2.5 Key Companies Time to Begin Mass Production of Recombinant Plasma Proteins 2.6 Recombinant Plasma Proteins Market Competitive Analysis 2.6.1 Recombinant Plasma Proteins Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Recombinant Plasma Proteins Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Proteins as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Chinese Hamster Ovary (CHO) Cell Line 3.1.2 Baby Hamster Kidney (BHK) Cell Line 3.1.3 Human Embryonic Kidney (HEK) Cell Line 3.1.4 Others 3.2 Global Recombinant Plasma Proteins Sales Value by Type 3.2.1 Global Recombinant Plasma Proteins Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Recombinant Plasma Proteins Sales Value, by Type (2019-2030) 3.2.3 Global Recombinant Plasma Proteins Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hemophilia A 4.1.2 Hemophilia B 4.1.3 Von Willebrand Disease 4.1.4 Others 4.2 Global Recombinant Plasma Proteins Sales Value by Application 4.2.1 Global Recombinant Plasma Proteins Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Recombinant Plasma Proteins Sales Value, by Application (2019-2030) 4.2.3 Global Recombinant Plasma Proteins Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Recombinant Plasma Proteins Sales Value by Region 5.1.1 Global Recombinant Plasma Proteins Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Recombinant Plasma Proteins Sales Value by Region (2019-2024) 5.1.3 Global Recombinant Plasma Proteins Sales Value by Region (2025-2030) 5.1.4 Global Recombinant Plasma Proteins Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Recombinant Plasma Proteins Sales Value, 2019-2030 5.2.2 North America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030 5.3.2 Europe Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Recombinant Plasma Proteins Sales Value, 2019-2030 5.4.2 Asia Pacific Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Recombinant Plasma Proteins Sales Value, 2019-2030 5.5.2 South America Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Recombinant Plasma Proteins Sales Value, 2019-2030 5.6.2 Middle East & Africa Recombinant Plasma Proteins Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Recombinant Plasma Proteins Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Recombinant Plasma Proteins Sales Value 6.3 United States 6.3.1 United States Recombinant Plasma Proteins Sales Value, 2019-2030 6.3.2 United States Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Recombinant Plasma Proteins Sales Value, 2019-2030 6.4.2 Europe Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Recombinant Plasma Proteins Sales Value, 2019-2030 6.5.2 China Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.5.3 China Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Recombinant Plasma Proteins Sales Value, 2019-2030 6.6.2 Japan Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Recombinant Plasma Proteins Sales Value, 2019-2030 6.7.2 South Korea Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Recombinant Plasma Proteins Sales Value, 2019-2030 6.8.2 Southeast Asia Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Recombinant Plasma Proteins Sales Value, 2019-2030 6.9.2 India Recombinant Plasma Proteins Sales Value by Type (%), 2023 VS 2030 6.9.3 India Recombinant Plasma Proteins Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 CSL Limited 7.1.1 CSL Limited Profile 7.1.2 CSL Limited Main Business 7.1.3 CSL Limited Recombinant Plasma Proteins Products, Services and Solutions 7.1.4 CSL Limited Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.1.5 CSL Limited Recent Developments 7.2 Shire (Takeda Pharmaceutical Company Limited) 7.2.1 Shire (Takeda Pharmaceutical Company Limited) Profile 7.2.2 Shire (Takeda Pharmaceutical Company Limited) Main Business 7.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Products, Services and Solutions 7.2.4 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments 7.3 Octapharma 7.3.1 Octapharma Profile 7.3.2 Octapharma Main Business 7.3.3 Octapharma Recombinant Plasma Proteins Products, Services and Solutions 7.3.4 Octapharma Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.3.5 Novo Nordisk Recent Developments 7.4 Novo Nordisk 7.4.1 Novo Nordisk Profile 7.4.2 Novo Nordisk Main Business 7.4.3 Novo Nordisk Recombinant Plasma Proteins Products, Services and Solutions 7.4.4 Novo Nordisk Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.4.5 Novo Nordisk Recent Developments 7.5 Bayer 7.5.1 Bayer Profile 7.5.2 Bayer Main Business 7.5.3 Bayer Recombinant Plasma Proteins Products, Services and Solutions 7.5.4 Bayer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.5.5 Bayer Recent Developments 7.6 Bioverativ Therapeutics, Inc. (Sanofi) 7.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Profile 7.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Main Business 7.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Products, Services and Solutions 7.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Developments 7.7 Aptevo Therapeutics 7.7.1 Aptevo Therapeutics Profile 7.7.2 Aptevo Therapeutics Main Business 7.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Products, Services and Solutions 7.7.4 Aptevo Therapeutics Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.7.5 Aptevo Therapeutics Recent Developments 7.8 Pharming Group 7.8.1 Pharming Group Profile 7.8.2 Pharming Group Main Business 7.8.3 Pharming Group Recombinant Plasma Proteins Products, Services and Solutions 7.8.4 Pharming Group Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.8.5 Pharming Group Recent Developments 7.9 Pfizer 7.9.1 Pfizer Profile 7.9.2 Pfizer Main Business 7.9.3 Pfizer Recombinant Plasma Proteins Products, Services and Solutions 7.9.4 Pfizer Recombinant Plasma Proteins Revenue (US$ Million) & (2019-2024) 7.9.5 Pfizer Recent Developments 8 Industry Chain Analysis 8.1 Recombinant Plasma Proteins Industrial Chain 8.2 Recombinant Plasma Proteins Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Recombinant Plasma Proteins Sales Model 8.5.2 Sales Channel 8.5.3 Recombinant Plasma Proteins Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
QYResearch社の医療分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |